Rexahn Pharmaceuticals (RNN) Publishes New Data on Anti-Cancer Isoquinolinamine Derivatives
ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry [45:5493-5497, 2010].
In the study, various substituted 3-aryl-1-isoquinolinamine derivatives were shown to have excellent cytotoxicity against eight different human cancer cells (breast, prostate, colon, ovary, kidney, pancreas, glioblastoma, melanoma). These derivatives were synthesized and evaluated through the constructed QSAR (quantitative structure-activity relationship) model and in vitro cell studies. QSAR technique is used in drug design and virtual screening to find lead compounds. The cytotoxic activities of new designed compounds are calculated using the constructed QSAR model and compared with actual cytotoxic data using the synthesized compounds.
“In this second published study, we further establish that isoquinolinamine derivatives, such as our anti-cancer compound RX-8243 – a new chemical entity – are potent anti-cancer compounds that have the potential to be developed into chemotherapeutic agents,” said Rick Soni, President of Rexahn.
Last month Rexahn announced the publication of new preclinical data in Bioorganic & Medicinal Chemistry Letters demonstrating that RX-8243, an isoquinolinamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing best in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ – all potential best in class therapeutics – and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn’s licensees or sublicensees; the success of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
TraderPower Featured Companies
- Aditxt Inc. (NASDAQ: ADTX)
- Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)
- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
- Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)
- Cepton Inc. (NASDAQ: CPTN)
- CISO Global, Inc. (NASDAQ: CISO)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Correlate Infrastructure Partners Inc. (OTCQB: CIPI)
- Cybin Inc. (NYSE American: CYBN) (NEO: CYBN)
- Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)
- EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)
- Flora Growth Corp. (NASDAQ: FLGC)
- Freight Technologies Inc. (NASDAQ: FRGT)
- HeartBeam Inc. (NASDAQ: BEAT)
- Golden Matrix Group Inc. (NASDAQ: GMGI)
- InMed Pharmaceuticals Inc. (NASDAQ: INM)
- Knightscope, Inc. (NASDAQ: KSCP)
- Lexaria Bioscience Corp. (NASDAQ: LEXX)
- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)
- Mullen Automotive Inc. (NASDAQ: MULN)
- QSAM Biosciences Inc. (OTCQB: QSAM)
- Tingo Inc. (OTC: TMNA)
- Vision Energy Corp. (OTCQB: VENG)
Top Small Cap Market News
- $FLGC CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space
- $ADTX Researchers ID Substance That Could Make Autoimmune Disease Treatment Possible
- $AZMCF Copper Sales Help Ivanhoe Register Record 2022 Profits
- $CPTN InvestorNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Announces CEO’s Panel Participation in Upcoming EV/Auto Tech Virtual Conference
- $CISO InvestorNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Releases Preliminary Quarter, FY Financial Report
- $CNSP Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy
- $QBTS D-Wave Quantum Inc. (NYSE: QBTS) Combines Power of Quantum Computing with Cloud, Machine Learning, to Fuel Business Efficiencies, Innovation
- $QBTS InvestorNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Launch of New Hybrid Solver Plug-In
- $BEAT HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults
- $KSCP InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds to Growing Orders, Marks 75th Stop in Robot Roadshow Schedule
- $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs
- $MUX MiningNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Positioned to Advanced Los Azules, Address Rising Demand for Copper
- $MULN InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Enters Licensing Agreement with Qiantu Motors to Manufacture, Distribute EV Supercar
Recent Posts
- $MULN InvestorNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Enters Licensing Agreement with Qiantu Motors to Manufacture, Distribute EV Supercar
- $MUX MiningNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Positioned to Advanced Los Azules, Address Rising Demand for Copper
- $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Tracking Proprietary Path to Drug Delivery Innovation and Commercialization on Robust R&D Programs
- $KSCP InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds to Growing Orders, Marks 75th Stop in Robot Roadshow Schedule
- $BEAT HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults
- $QBTS InvestorNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Launch of New Hybrid Solver Plug-In
- $QBTS D-Wave Quantum Inc. (NYSE: QBTS) Combines Power of Quantum Computing with Cloud, Machine Learning, to Fuel Business Efficiencies, Innovation
- $CNSP Normalizing Blood Vessels in Tumors Could Improve Brain Cancer Immunotherapy
Recent Comments
Archives
- March 2023
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009